Geno­cea reach­es end of road, delist­ing from Nas­daq and let­ting go of re­main­ing staff

A piv­ot in­to neoanti­gen im­munother­a­pies was not enough to save Geno­cea Bio­sciences af­ter all.

The 16-year-old biotech said it would be clos­ing down and lay­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER